Literature DB >> 12065630

Injury-induced "switch" from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord.

Barry W Festoff1, Karen SantaCruz, Paul M Arnold, Cyril T Sebastian, Peter J A Davies, Bruce A Citron.   

Abstract

We recently found that alternative transcripts of tissue transglutaminase (tTG or TG2) were present in hippocampal brain regions of Alzheimer's disease (AD), but not in control, non-demented, age-matched brains. Since antecedent non-severe trauma has been implicated in AD and other neurodegenerative diseases, such as Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), we were interested in whether alternative transcripts might be detected in a model of neurotrauma, controlled-contusion spinal cord injury (SCI) in the rat. Implicated in diverse roles from growth and differentiation to apoptotic cell death, only bifunctional tTG, of the nine member TG family, has dual catalytic activities: guanine trinucleotide (GTP) hydrolyzing activity (GTPase), as well as protein cross-linking. These functions imply two physiological functions: programmed cell life and death. These may have profound roles in the nervous system since studies in cultured astrocytes found tTG short (S) mRNA transcripts induced by treatment with injury-related cytokines. In the developing rat spinal cord, tTG activity is concentrated in ventral horn alpha motoneurons, but neither studies of spinal cord tTG gene expression, nor evaluation of the GTP-regulated isoforms in tissues, have been reported. We now report increased tTG protein and gene expression occurring rapidly after SCI. In parallel, novel appearance of a second, short form transcript, in addition to the normal long (L) isoform, occurs by 8 h of injury. Up-regulation of tTG message and activity following neural injury. with appearance of a truncated GTP-unregulated S form, may represent new approaches to drug targets in neurotrauma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065630     DOI: 10.1046/j.1471-4159.2002.00850.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

Review 1.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

2.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

Review 3.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 4.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

5.  The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.

Authors:  Garima Singh; Jingwen Zhang; Yilun Ma; Richard A Cerione; Marc A Antonyak
Journal:  J Biol Chem       Date:  2016-02-18       Impact factor: 5.157

6.  The Differential Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 Transglutaminase.

Authors:  Qingmin Ruan; Janusz Tucholski; Soner Gundemir; Gail V W Johnson Voll
Journal:  Int J Clin Exp Med       Date:  2008-06-30

7.  Anti transglutaminase antibodies cause ataxia in mice.

Authors:  Sabrina Boscolo; Andrea Lorenzon; Daniele Sblattero; Fiorella Florian; Marco Stebel; Roberto Marzari; Tarcisio Not; Daniel Aeschlimann; Alessandro Ventura; Marios Hadjivassiliou; Enrico Tongiorgi
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

Review 8.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

Review 9.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.

Authors:  Manuela Basso; Jill Berlin; Li Xia; Sama F Sleiman; Brendan Ko; Renee Haskew-Layton; Eunhee Kim; Marc A Antonyak; Richard A Cerione; Siiri E Iismaa; Dianna Willis; Sunghee Cho; Rajiv R Ratan
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.